Literature DB >> 11296485

Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells.

A Catania1, S Urban, E Yan, C Hao, G Barron, J Allalunis-Turner.   

Abstract

Cyclin-dependent kinase 5 (Cdk5), a member of the cyclin-dependent kinase family, is expressed predominately in mature neurons and is implicated in neurite extension, neuronal migration, and neuronal differentiation. Cdk5 protein expression also has been associated with apoptosis in a number of nonneuronal model systems. In normal brain, substrates for Cdk5 include neurofilament and tau proteins. Because human tumors of glial origin can express neuronal proteins, we examined whether Cdk5 and its activator protein, P35, are present in early passage human glioblastoma multiforme (GBM) cells lines and primary tumor specimens. Here we report the expression of Cdk5 and an "active" proteolytic form of P35 in human GBM cells and demonstrate kinase activity of the holoenzyme. We also show that Cdk5 kinase activity and expression of its activator protein, P35, is increased in the human GBM cell line M059J after exposure to ionizing radiation and that P35 is localized within M059J cells undergoing apoptosis. These results suggest a possible role for Cdk5 in mediating apoptosis in human GBM cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296485      PMCID: PMC1920606          DOI: 10.1093/neuonc/3.2.89

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  9 in total

Review 1.  The Emerging Role of Cdk5 in Cancer.

Authors:  Karine Pozo; James A Bibb
Journal:  Trends Cancer       Date:  2016-10

2.  O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation.

Authors:  Lorela Ciraku; Zachary A Bacigalupa; Jing Ju; Rebecca A Moeller; Giang Le Minh; Rusia H Lee; Michael D Smith; Christina M Ferrer; Sophie Trefely; Luke T Izzo; Mary T Doan; Wiktoria A Gocal; Luca D'Agostino; Wenyin Shi; Joshua G Jackson; Christos D Katsetos; Kathryn E Wellen; Nathaniel W Snyder; Mauricio J Reginato
Journal:  Oncogene       Date:  2022-02-22       Impact factor: 8.756

3.  Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients.

Authors:  Xin Zhang; Tengfei Zhong; Yiwu Dang; Zuyun Li; Ping Li; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion.

Authors:  Ren Liu; Bo Tian; Marla Gearing; Stephen Hunter; Keqiang Ye; Zixu Mao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-16       Impact factor: 11.205

Review 5.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

6.  Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.

Authors:  Ruan Yushan; Chen Wenjie; Huang Suning; Dang Yiwu; Zhong Tengfei; Wickramaarachchi Mihiranganee Madushi; Luo Feifei; Zhang Changwen; Wen Xin; Gopaul Roodrajeetsing; Li Zuyun; Chen Gang
Journal:  World J Surg Oncol       Date:  2015-07-25       Impact factor: 2.754

7.  Mitochondrial control by DRP1 in brain tumor initiating cells.

Authors:  Qi Xie; Qiulian Wu; Craig M Horbinski; William A Flavahan; Kailin Yang; Wenchao Zhou; Stephen M Dombrowski; Zhi Huang; Xiaoguang Fang; Yu Shi; Ashley N Ferguson; David F Kashatus; Shideng Bao; Jeremy N Rich
Journal:  Nat Neurosci       Date:  2015-03-02       Impact factor: 24.884

8.  Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells.

Authors:  Carrie DeHaan; Bahram Habibi-Nazhad; Elizabeth Yan; Nicole Salloum; Matthew Parliament; Joan Allalunis-Turner
Journal:  Mol Cancer       Date:  2004-07-12       Impact factor: 27.401

Review 9.  The Role of Network Science in Glioblastoma.

Authors:  Marta B Lopes; Eduarda P Martins; Susana Vinga; Bruno M Costa
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.